- Home
- HTBI vs MBX Comparison
HTBI vs MBX Comparison
Compare HTBI & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- MBX
- Stock Information
- Founded
- HTBI 1926
- MBX 36
- Country
- HTBI United States
- MBX United States
- Employees
- HTBI N/A
- MBX N/A
- Industry
- HTBI Savings Institutions
- MBX
- Sector
- HTBI Finance
- MBX
- Exchange
- HTBI Nasdaq
- MBX NYSE
- Market Cap
- HTBI 661.4M
- MBX 762.6M
- IPO Year
- HTBI 2012
- MBX 2024
- Fundamental
- Price
- HTBI $37.34
- MBX $17.61
- Analyst Decision
- HTBI Buy
- MBX Strong Buy
- Analyst Count
- HTBI 4
- MBX 4
- Target Price
- HTBI $37.67
- MBX $37.25
- AVG Volume (30 Days)
- HTBI 54.4K
- MBX 90.9K
- Earning Date
- HTBI 10-24-2024
- MBX 11-07-2024
- Dividend Yield
- HTBI 1.28%
- MBX N/A
- EPS Growth
- HTBI 14.18
- MBX N/A
- EPS
- HTBI 3.52
- MBX N/A
- Revenue
- HTBI $187,440,000.00
- MBX N/A
- Revenue This Year
- HTBI N/A
- MBX N/A
- Revenue Next Year
- HTBI N/A
- MBX N/A
- P/E Ratio
- HTBI $10.62
- MBX N/A
- Revenue Growth
- HTBI 2.84
- MBX N/A
- 52 Week Low
- HTBI $22.31
- MBX $17.01
- 52 Week High
- HTBI $38.62
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- HTBI 62.42
- MBX N/A
- Support Level
- HTBI $36.98
- MBX N/A
- Resistance Level
- HTBI $38.60
- MBX N/A
- Average True Range (ATR)
- HTBI 1.14
- MBX 0.00
- MACD
- HTBI 0.37
- MBX 0.00
- Stochastic Oscillator
- HTBI 79.87
- MBX 0.00
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.